Antibacterial activity of the novel semisynthetic lantibiotic NVB333 in vitro and in experimental infection models (Q40670947)

22 September 2017

title

Antibacterial activity of the novel semisynthetic lantibiotic NVB333 in vitro and in experimental infection models (English)

1 reference

22 September 2017

main subject

experimental infection

1 reference

Steven Boakes

1

1 reference

22 September 2017

William J Weiss

2

1 reference

22 September 2017

Mary Vinson

3

1 reference

22 September 2017

Sjoerd Wadman

4

1 reference

22 September 2017

Michael J Dawson

5

1 reference

22 September 2017

language of work or name

1 reference

18 May 2016

1 reference

The Journal of Antibiotics

22 September 2017

published in

1 reference

22 September 2017

volume

69

1 reference

22 September 2017

issue

12

1 reference

22 September 2017

page(s)

850-857

1 reference

Antibiotics in the clinical pipeline in 2013.

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

Fighting bacterial infections-future treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

Lantibiotics: promising candidates for future applications in health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by Actinoplanes liguriae NCIMB41362.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

Lantibiotics: mode of action, biosynthesis and bioengineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

A new antibiotic kills pathogens without detectable resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

Pharmacokinetic and pharmacodynamic evaluation of the lantibiotic MU1140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

In vivo efficacy and pharmacokinetics of AC98-6446, a novel cyclic glycopeptide, in experimental infection models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

sigmaB modulates virulence determinant expression and stress resistance: characterization of a functional rsbU strain derived from Staphylococcus aureus 8325-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

Synthesis and biological activity of some amide derivatives of the lantibiotic actagardine.

21 January 2018

1 reference

12 December 2020

In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

1 reference

12 December 2020

The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II.

1 reference

12 December 2020

Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity

1 reference

12 December 2020

Discovery and Development of NVB302, a Semisynthetic Antibiotic for Treatment of Clostridium difficile Infection

1 reference

https://api.crossref.org/works/10.1038%2FJA.2016.47

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/JA.2016.47

1 reference

release_6zu4zj2ttjbktclwl6nv7hqbna

22 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6zu4zj2ttjbktclwl6nv7hqbna

24 November 2022

mapped directly with Wikidata item

1 reference